Curated News
By: NewsRamp Editorial Staff
June 30, 2026

BioElectronics Posts Profit, Advances Non-Opioid Pain Therapy Initiatives

Discuss on Substack Discuss on Telegram
Original Source

TLDR

  • BioElectronics (BIEL) reports 2025 profit, expanded advertising, and new Electrome order, signaling growth potential for shareholders.
  • BioElectronics cuts costs, runs targeted ads for RecoveryRx, seeks clinical trial partners, and fulfills Electrome supply agreement for pulsed shortwave therapy.
  • BioElectronics promotes non-opioid pain relief via RecoveryRx, aiming to reduce opioid dependence and improve patient outcomes in surgical and chronic care.
  • BioElectronics pursues NO PAIN Act reimbursement for RecoveryRx, potentially making drug-free pain management standard after surgery.

Impact - Why it Matters

This news matters because it highlights a growing shift toward non-opioid pain management solutions, which could reduce reliance on addictive painkillers. BioElectronics' progress, including profitability and strategic partnerships, signals that drug-free technologies like RecoveryRx are gaining traction in both clinical and consumer markets. For patients and healthcare providers, increased adoption of these FDA-cleared devices may offer safer, effective alternatives for managing pain, particularly in surgical settings where the NO PAIN Act could enhance access. Shareholders and investors should note the company's disciplined financial management and potential for future growth through reimbursement pathways and expanded distribution.

Summary

BioElectronics Corporation (OTC: BIEL) has released an update from its Chairman, Richard Staelin, PhD, detailing the company's strategic progress and financial improvements. The medical technology developer reported a small profit for calendar year 2025, achieved through disciplined cost control measures including office relocation and staff reductions. The company is executing multiple initiatives to expand awareness and adoption of its non-opioid pain management technologies, particularly its flagship product RecoveryRx.

A key focus is targeted advertising campaigns directed at medical professionals and healthcare providers, aiming to increase clinical awareness of RecoveryRx among surgeons, pain specialists, and chiropractors seeking non-opioid pain management options. Additionally, consumer-focused social media advertising targets Generation X consumers to boost brand visibility for drug-free solutions to chronic musculoskeletal pain. The company is also pursuing outreach to physician-owned ambulatory surgical centers and orthopedic practices to identify a clinical trial partner for RecoveryRx, with the goal of supporting future qualification for reimbursement under the federal NO PAIN Act initiative. This represents a meaningful long-term opportunity for broader adoption of non-opioid pain management technologies in surgical settings.

Internationally, BioElectronics continues arbitration proceedings in Singapore involving a former distributor, protecting its intellectual property and contractual rights. The company also announced a strategic distribution and licensing relationship with Electrome Corporation, with manufacturing underway and a commercial launch planned for its pulsed shortwave therapy products. This milestone provides another pathway to increase consumer awareness and access to FDA-cleared, drug-free pain therapy products. Despite challenges facing emerging medical technology companies, BioElectronics remains encouraged by growing interest in non-drug pain management and is well-positioned in the evolving electroceutical market. The company is committed to advancing initiatives that support sustainable growth and building long-term value for shareholders.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, BioElectronics Posts Profit, Advances Non-Opioid Pain Therapy Initiatives

blockchain registration record for this content.